GLP-1 Comparison Guide 2026
GLP-1 Comparison Guide 2026
I’m an ER and Family Medicine physician in Chattanooga, Tennessee, and I read every patient chart at Summit personally. These articles give honest, evidence-based answers about GLP-1 medications and metabolic health.
The question I get most often from people considering GLP-1 therapy: “Which one should I take?” It sounds simple. The answer isn’t. The right GLP-1 medication depends on your metabolic health profile, your cardiovascular risk, whether you have type 2 diabetes, your tolerance for injections, your budget, and what your goals are beyond the number on the scale.
This guide covers every major GLP-1 medication currently available in 2026 — injectable and oral — with current pricing, weight loss data, and the metabolic profile each one is best suited for.
The injectable GLP-1s: what changed and what the data shows
Ozempic is FDA-approved for type 2 diabetes management, not specifically for weight loss — though off-label use for weight loss is common. The SUSTAIN trial program established robust cardiovascular safety data, including a 26% reduction in major cardiovascular events in patients with established cardiovascular disease. At the 2 mg dose, average weight loss in the SUSTAIN-11 trial was approximately 9.6%. The strongest evidence for cardiovascular benefit makes Ozempic a particularly appropriate choice for patients with existing heart disease, prior stroke, or high cardiovascular risk, regardless of whether they have a T2D diagnosis.
*Self-pay pricing reflects new affordability programs; see pricing section below.
Wegovy is the weight-management-approved formulation of semaglutide at the higher 2.4 mg dose. STEP-1 demonstrated 14.9% average weight loss over 68 weeks. The SELECT trial (2023) showed a 20% reduction in major cardiovascular events — the first weight-loss medication to demonstrate cardiovascular benefit in a dedicated outcomes trial. Wegovy also received the first FDA approval for fatty liver disease (MASH) in 2025. The SELECT cardiovascular data makes Wegovy specifically compelling for patients with metabolic syndrome, fatty liver, or elevated cardiovascular risk.
The highest-dose semaglutide approved to date. STEP UP trial data shows approximately 20% average weight loss — closing the gap with tirzepatide. The tradeoff: dysesthesia (skin sensitivity) affects 22.9% of patients at this dose versus 6% at the 2.4 mg dose, making slow titration and patient counseling essential. Best suited for patients who have plateaued on 2.4 mg and want to continue semaglutide rather than switching agents.
Tirzepatide achieves the highest average weight loss of any currently approved injectable GLP-1 RA — 20.9% at the 15 mg dose in SURMOUNT-1. The dual GLP-1/GIP mechanism appears to address insulin resistance more broadly than GLP-1 alone, with GIP’s direct effect on adipose tissue insulin sensitivity. SURMOUNT-2 demonstrated 15.7% weight loss in patients with type 2 diabetes — higher than any semaglutide trial in T2D patients. The metabolic case for tirzepatide is strongest in patients with significant insulin resistance, T2D, and those who want maximum weight loss effect. The SURPASS-CVOT trial demonstrated cardiovascular safety; cardiovascular benefit outcomes data are pending.
The oral GLP-1s: a new category as of 2025–2026
Two important oral GLP-1 medications launched in 2025–2026, dramatically expanding options for patients who can’t or won’t self-inject. The tradeoffs are real and worth understanding before choosing oral over injectable.
The OASIS 4 trial demonstrated 16.6% average weight loss at 72 weeks — comparable to injectable Wegovy — making this a genuine alternative to injection for appropriate patients. Critical requirement: the tablet must be taken with no more than 4 oz of water, at least 30 minutes before food or other medications. This fasting window is mandatory for adequate absorption and is a meaningful adherence challenge for some patients. Best suited for needle-averse patients who can reliably maintain the fasting protocol and who are motivated by the convenience of not managing injectable supplies.
The first non-peptide (small molecule) GLP-1 receptor agonist approved. Unlike oral semaglutide — which is still a peptide requiring special absorption protocols — orforglipron is a small molecule taken like any conventional pill, with no food or timing restrictions. This represents a meaningful convenience advantage. The tradeoff: lower average weight loss (~11–12%) compared to injectable tirzepatide or semaglutide. Best suited for patients who prioritize maximum convenience and tolerability over maximum weight loss, or who want to start GLP-1 therapy without injection commitment. Currently exclusively available through Found Health’s telehealth platform as Foundayo.
What everything actually costs in 2026
Pricing for GLP-1 medications transformed in 2025–2026. Many comparison articles still cite the old $1,000+/month cash-pay figures. That retail number is real, but almost nobody pays it any more — both manufacturers now sell direct to consumers at a fraction of list, and that is the number that decides what a given person can actually afford.
One thing worth saying plainly: in both programs the lowest price is on the vials you draw with a syringe, not the pre-filled auto-injector pens. Choosing on price also means choosing a syringe. That is a fair trade for a lot of people — but it should be a decision, not a surprise.
Wegovy — Novo Nordisk cash & savings program
| Product and dose | Cash price |
|---|---|
| Injections — starter doses 0.25 mg & 0.5 mg | $199/mo for the first two months, then $349/mo |
| Injections — maintenance doses 1 mg to 2.4 mg | $349/mo |
| Injections — high dose 7.2 mg | $399/mo |
| Pills — lower doses 1.5 mg & 4 mg | $149/mo — the 4 mg promotional price ends 31 August 2026, then $199/mo |
| Pills — higher doses 9 mg & 25 mg | $299/mo |
Zepbound — Eli Lilly (LillyDirect)
| Product and dose | Cash price |
|---|---|
| Vials — 2.5 mg starter dose | $299/mo |
| Vials — 5 mg | $399/mo |
| Vials and KwikPen — 7.5 mg to 15 mg | $449/mo (must refill within 45 days) |
| Retail list price — pre-filled injector pens | $1,086.37 per 28-day supply |
Two other Zepbound routes. If you have commercial health insurance that flatly denies weight-loss coverage, Lilly’s savings card brings the standard pens to roughly $550/month — but anyone on Medicare, Medicaid or Tricare is legally excluded from using it. At a retail pharmacy, third-party discount cards land around $599/month (GoodRx) or $490–$655/month (SingleCare).
Insurance, where it applies: most commercial plans that cover these medications land the patient at a $0–$25 copay. Coverage is strongest for Ozempic and Mounjaro under a type 2 diabetes indication, and far more variable for weight management.
Ozempic (semaglutide, for type 2 diabetes). Novo’s published list price is $1,027.51 per package. Its self-pay program runs $199/month for the first two fills at the 0.25 and 0.5 mg starter doses (new patients, through 31 December 2026), then $349/month; 1 mg is $349/month and 2 mg is $499/month. The oral form runs $149, $199 and $299/month by dose. If you have commercial insurance that covers it, a separate copay card can bring it to as little as $25/month — but Medicare, Medicaid and Tricare beneficiaries are excluded from that one by law.
Liraglutide (generic) and Foundayo: we are deliberately not printing a monthly figure for these. Liraglutide is priced per pen rather than per month, and a pen lasts fifteen days at one dose and ten days at another — so any “per month” number is arithmetic, not a published price. Ask us and we will price it for your actual dose.
Matching medication to your metabolic profile
This is the framework no competitor comparison uses — and the most clinically relevant way to approach the decision.
Significant insulin resistance (high fasting insulin, elevated Trig/HDL ratio, prediabetes/T2D):
First choice: Tirzepatide (Mounjaro/Zepbound) — dual GIP/GLP-1 mechanism provides the broadest insulin-sensitizing effect. Most evidence for improving insulin sensitivity in adipose tissue specifically.
Established cardiovascular disease, prior stroke, or high CV risk:
First choice: Semaglutide (Ozempic/Wegovy) — SELECT trial demonstrated 20% reduction in MACE in high-CV-risk patients. Most robust cardiovascular outcomes data of any GLP-1 RA to date.
Fatty liver disease (MASH/NAFLD):
First choice: Semaglutide (Wegovy) — only GLP-1 RA with FDA approval specifically for MASH. Strong Phase 3 data showing histological improvement.
Needle aversion, maximum convenience:
First choice: Oral semaglutide (Wegovy pill) if adherent to fasting protocol, or orforglipron if no fasting requirement is the priority. Both involve meaningful tradeoffs in weight loss vs. injectable options.
Maximum weight loss as primary goal:
First choice: Tirzepatide 15 mg (20–22% average) or Semaglutide 7.2 mg HD (~20%), with the caveat that higher doses increase side effect burden and require close clinical management.
Women over 40 / post-menopausal:
Specific consideration: tirzepatide’s GIP mechanism may provide better lean mass preservation vs. pure GLP-1 agonists — an important factor given post-menopausal sarcopenia risk. Protein targeting and resistance training are mandatory alongside any medication choice.
The pipeline: what’s coming in 2026–2027
The GLP-1 landscape is still evolving rapidly. These medications are in Phase 3 trials or pending approval and are worth knowing about if you’re deciding whether to start now or wait:
- Retatrutide (Eli Lilly) — Triple agonist (GLP-1 + GIP + glucagon). Phase 3 data showing 24–29% weight loss — the highest yet documented. NDA submission expected 2026. Glucagon agonism adds a direct fat-burning mechanism not present in current agents
- CagriSema (Novo Nordisk) — Combination of cagrilintide (amylin analog) and semaglutide. Phase 3 showing ~20% weight loss with potentially different side effect profile. Amylin agonism may better preserve lean mass
- MariTide (Amgen) — Monthly injection. Phase 3 ongoing. If approved, monthly dosing would be a significant convenience advance over weekly injections
- Oral tirzepatide — Eli Lilly has announced development of an oral formulation. No timeline confirmed at publication
The question behind the question
The real question isn’t “which GLP-1 is best?” It’s “which GLP-1 is best for my metabolic profile, health history, and goals?” Those are different questions — and the second one requires a physician who reviews your metabolic labs, not just your BMI.
The comparison apps and quiz-based telehealth platforms will give you a medication recommendation in minutes based on your height, weight, and self-reported health history. That’s not a metabolic evaluation. It’s a transaction.
At Summit Metabolic Health, the consultation starts with a review of your metabolic markers — fasting insulin, A1C, triglyceride/HDL ratio, liver enzymes, CRP. We use that data to determine which medication matches your biology, not just your scale number. That’s the difference between a prescription and a treatment plan.
Ready for a physician-led evaluation that matches your GLP-1 medication to your actual metabolic profile? Summit Metabolic Health. Telehealth, cash-pay, Tennessee patients.
Book a Consultation →Pricing data reflects April 2026 publicly available information and is subject to change. This article is for educational purposes only and does not constitute individualized medical advice. Brand names are used for identification only. Consult your physician before starting any medication. © 2026 Summit Metabolic Health · www.summitmetabolichealth.com